Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for Long-Term control of rare muscle disease

NCT ID NCT05332210

First seen Apr 30, 2026 · Last updated May 24, 2026 · Updated 5 times

Summary

This study looked at the long-term safety of a drug called HBM9161 for people with generalized myasthenia gravis, a condition that causes muscle weakness. A total of 111 patients who had already completed an earlier study took part. The goal was to see if the drug is safe to use over a longer period alongside their usual treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

Conditions

Explore the condition pages connected to this study.